U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07297654) titled 'First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment' on Dec. 09.
Brief Summary: This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Hepatocellular Carcinoma
Intervention:
DRUG: Lenvatinib
Lenvatinib will be administered orally at a dose of 8 mg once daily at the same time each day, with or without food (regardless of body weight). For participants with a baseline body weight >=60 kg who tolerate l...